Efficacy of BRL43694, a New Anti-Emetic
Author Information
Author(s): J. Cassidy, V. Raina, C. Lewis, L. Adams, M. Soukop, W.G. Rapeport, B.D. Zussman, E.M. Rankin, S.B. Kaye
Primary Institution: CRC Department of Medical Oncology, Glasgow Royal Infirmary, Beecham Pharmaceuticals
Hypothesis
Can BRL43694 effectively reduce nausea and vomiting in patients undergoing chemotherapy?
Conclusion
BRL43694 is an effective and well-tolerated anti-emetic for patients receiving chemotherapy.
Supporting Evidence
- Eleven patients were completely protected from vomiting.
- BRL43694 was well tolerated with no adverse effects observed.
- Four patients experienced immediate termination of vomiting after BRL43694 was administered.
Takeaway
This study tested a new medicine called BRL43694 to help stop people from feeling sick and throwing up after cancer treatment, and it worked well for many patients.
Methodology
Twenty patients received a single intravenous infusion of BRL43694 after chemotherapy, and their nausea and vomiting were assessed.
Limitations
The study had a small sample size and did not establish a clear relationship between timing of administration and efficacy.
Participant Demographics
9 females and 11 males with a mean age of 49.8 years; 17 were chemotherapy naive.
Want to read the original?
Access the complete publication on the publisher's website